Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838575 | 1.00 | GCK (1.00) | GCKKCNH2 | |
| SCHEMBL838708 | 0.93 | GCK (0.87) | GCKKCNH2 | |
| SCHEMBL13112043 | 0.93 | GCK (0.86) | GCKKCNH2 | |
| SCHEMBL13143987 | 0.92 | GCK (0.85) | GCKKCNH2 | |
| SCHEMBL849606 | 0.92 | GCK (0.85) | GCKKCNH2 | |
| SCHEMBL838826 | 0.92 | GCK (0.85) | GCKKCNH2 | |
| SCHEMBL838547 | 0.89 | GCK (1.00) | GCKKCNH2 | |
| SCHEMBL838883 | 0.89 | GCK (0.80) | GCKKCNH2 | |
| SCHEMBL838882 | 0.89 | GCK (0.80) | GCKKCNH2 | |
| SCHEMBL838074 | 0.89 | GCK (0.90) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011529955-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-8071585-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | claimed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | claimed |
| WO-2010116177-A1 | A PYRAZOLO [4,5-E] PYRIMIDINE DERIVATIVE AND ITS USE TO TREAT DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | claimed |
| US-20100261704-A1 | THERAPEUTIC AGENTS 928 | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | claimed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | claimed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | claimed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8071585-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071585-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071585-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071585-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010116177-A1 | A PYRAZOLO [4,5-E] PYRIMIDINE DERIVATIVE AND ITS USE TO TREAT DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010116177-A1 | A PYRAZOLO [4,5-E] PYRIMIDINE DERIVATIVE AND ITS USE TO TREAT DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010116177-A1 | A PYRAZOLO [4,5-E] PYRIMIDINE DERIVATIVE AND ITS USE TO TREAT DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261704-A1 | THERAPEUTIC AGENTS 928 | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261704-A1 | THERAPEUTIC AGENTS 928 | GCK, GCKR, GALK1 | GCK 1/4885KCNH2 1066/4885 |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | GCK 1/4885KCNH2 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.